A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations

TAS0728 is an oral covalent binding inhibitor of human epidermal growth factor receptor 2 (HER2). A first-in-human open-label, dose-escalation, phase I study (NCT03410927) was initiated to investigate the safety and dose-limiting toxicity (DLT) and to determine the maximum tolerated dose (MTD) and/o...

Descripción completa

Detalles Bibliográficos
Autores principales: Piha-Paul, Sarina A., Azaro, Analía, Arkenau, Hendrik Tobias, Oh, Do-Youn, Galsky, Matthew D., Pal, Sumanta Kumar, Hamada, Kensuke, He, Yaohua, Yamamiya, Ikuo, Benhadji, Karim A, Hollebecque, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426237/
https://www.ncbi.nlm.nih.gov/pubmed/33774767
http://dx.doi.org/10.1007/s10637-021-01104-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426237/
https://www.ncbi.nlm.nih.gov/pubmed/33774767
http://dx.doi.org/10.1007/s10637-021-01104-7

Ejemplares similares